If you made any changes in Pure these will be visible here soon.

Personal profile

Education

  • 2007 Ph.D., National Taiwan University Pathology 
  • 1998 MS, National Taiwan University  Pathology  
  • 1996 BS.. China Medical University   Medical Technology   

Experience

  • 2013- School of Medical Laboratory Science and Biotechnology Assistant Professor
  • 2009 Seattle Childrens Research Institute fellow Ph.D
  • 2007 Department of medical Laboratory Science and Biotechnology fellow Ph.D.

Awards

  • 2011 53rd ASH abstract achievement awards- American Society of Hematology
  • 2013 55rd ASH abstract achievement awards- American Society of Hematology
  • 2013-2015 NSC University outstanding investigator recruitment award
  • 2016 Excellent research paper award-Teachers and students joint academic research symposium (TMU)

Research Interests

  • Immunotherapy

Fingerprint Dive into the research topics where Chao-Lien Liu is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 9 Similar Profiles
Factor VIII Medicine & Life Sciences
Hemophilia A Medicine & Life Sciences
Hepatocellular Carcinoma Medicine & Life Sciences
Interleukin-2 Medicine & Life Sciences
Carcinoma Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Cells Chemical Compounds
Cell growth Chemical Compounds

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 2013 2020

嵌合抗原受體T細胞用於治療人類卵巢癌的免疫療法(1/3)

Liu, C.

8/1/197/1/20

Project: A - Government Institutionb - Ministry of Science and Technology

劉兆蓮-107研究計畫績效獎

Liu, C.

8/1/187/31/20

Project: B - Project of TMUh - Other (Funded by TMU)

建構抗免疫監測點抑制因子PD1 與PDL1的嵌合抗原受體T 細胞來治療胰臟癌(3/3)

Liu, C.

8/1/187/1/19

Project: A - Government Institutionb - Ministry of Science and Technology

建構抗免疫監測點抑制因子PD1 與PDL1的嵌合抗原受體T 細胞來治療胰臟癌(2/3)

Liu, C.

8/1/177/31/18

Project: A - Government Institutionb - Ministry of Science and Technology

抗免疫監測點抑制因子PD1 與PDL1的嵌合抗原受體修飾性γδ-T細胞用於治療卵巢癌療效之探討

Liu, C.

7/1/172/28/18

Project: A - Government Institutionb - Ministry of Science and Technology

Research Output 2002 2019

  • 190 Citations
  • 7 h-Index
  • 14 Article

Ex vivo expanded human Vγ9vδ2 T-cells can suppress epithelial ovarian cancer cell growth

Mao, T. L., Miao, C. H., Liao, Y. J., Chen, Y. J., Yeh, C. Y. & Liu, C. L., Mar 1 2019, In : International Journal of Molecular Sciences. 20, 5, 1139.

Research output: Contribution to journalArticle

Open Access
T-cells
Cell growth
cancer
Tumors
T-Lymphocytes

HMGCS2 mediates ketone production and regulates the proliferation and metastasis of hepatocellular carcinoma

Wang, Y. H., Liu, C. L., Chiu, W. C., Twu, Y. C. & Liao, Y. J., Dec 2019, In : Cancers. 11, 12, 1876.

Research output: Contribution to journalArticle

Open Access
Hydroxymethylglutaryl-CoA Synthase
Ketones
Hepatocellular Carcinoma
Neoplasm Metastasis
Liver Neoplasms

SRPX and HMCN1 regulate cancer‑associated fibroblasts to promote the invasiveness of ovarian carcinoma

Liu, C. L., Pan, H. W., Torng, P. L., Fan, M. H. & Mao, T. L., Jan 1 2019, In : Oncology Reports. 42, 6, p. 2706-2715 10 p.

Research output: Contribution to journalArticle

Ovarian Neoplasms
Fibroblasts
Carcinoma
Proteins
Neoplasms

Treatment with a new benzimidazole derivative bearing a pyrrolidine side chain overcomes sorafenib resistance in hepatocellular carcinoma

Suk, F. M., Liu, C. L., Hsu, M. H., Chuang, Y. T., Wang, J. P. & Liao, Y. J., Dec 1 2019, In : Scientific Reports. 9, 1, 17259.

Research output: Contribution to journalArticle

Hepatocellular Carcinoma
Therapeutics
Epithelial-Mesenchymal Transition
Heterografts
Glypicans